Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 300

2.
3.

The role of immunohistochemistry for smooth-muscle actin, p63, CD10 and cytokeratin 14 in the differential diagnosis of papillary lesions of the breast.

Tse GM, Tan PH, Lui PC, Gilks CB, Poon CS, Ma TK, Law BK, Lam WW.

J Clin Pathol. 2007 Mar;60(3):315-20. Epub 2006 May 12.

4.

Intracystic papillary carcinomas of the breast: a reevaluation using a panel of myoepithelial cell markers.

Collins LC, Carlo VP, Hwang H, Barry TS, Gown AM, Schnitt SJ.

Am J Surg Pathol. 2006 Aug;30(8):1002-7.

PMID:
16861972
5.

Use of a novel marker, calponin, for myoepithelial cells in fine-needle aspirates of papillary breast lesions.

Mosunjac MB, Lewis MM, Lawson D, Cohen C.

Diagn Cytopathol. 2000 Sep;23(3):151-5.

PMID:
10945900
6.

Use of p63 and CD10 in the differential diagnosis of papillary neoplasms of the breast.

de Moraes Schenka NG, Schenka AA, de Souza Queiroz L, de Almeida Matsura M, Vassallo J, Alvarenga M.

Breast J. 2008 Jan-Feb;14(1):68-75. Epub 2007 Dec 11.

PMID:
18086274
7.

Diagnostic utility of p75 neurotrophin receptor (p75NTR) as a marker of breast myoepithelial cells.

Popnikolov NK, Cavone SM, Schultz PM, Garcia FU.

Mod Pathol. 2005 Dec;18(12):1535-41.

8.
9.
10.

p63, a p53 homologue, is a selective nuclear marker of myoepithelial cells of the human breast.

Barbareschi M, Pecciarini L, Cangi MG, Macrì E, Rizzo A, Viale G, Doglioni C.

Am J Surg Pathol. 2001 Aug;25(8):1054-60.

PMID:
11474290
11.

Cytokeratins in papillary lesions of the breast: is there a role in distinguishing intraductal papilloma from papillary ductal carcinoma in situ?

Tan PH, Aw MY, Yip G, Bay BH, Sii LH, Murugaya S, Tse GM.

Am J Surg Pathol. 2005 May;29(5):625-32.

PMID:
15832086
12.

Is core needle biopsy superior to fine-needle aspiration biopsy in the diagnosis of papillary breast lesions?

Masood S, Loya A, Khalbuss W.

Diagn Cytopathol. 2003 Jun;28(6):329-34.

PMID:
12768640
13.
15.

Immunohistochemical staining of papillary breast lesions.

Troxell ML, Masek M, Sibley RK.

Appl Immunohistochem Mol Morphol. 2007 Jun;15(2):145-53.

PMID:
17525625
16.

Immunohistochemical analysis of benign and malignant papillary lesions of the breast.

Papotti M, Eusebi V, Gugliotta P, Bussolati G.

Am J Surg Pathol. 1983 Jul;7(5):451-61.

PMID:
6351647
17.

Double immunostaining with p63 and high-molecular-weight cytokeratins distinguishes borderline papillary lesions of the breast.

Ichihara S, Fujimoto T, Hashimoto K, Moritani S, Hasegawa M, Yokoi T.

Pathol Int. 2007 Mar;57(3):126-32.

PMID:
17295644
18.

Phenotypic alterations in ductal carcinoma in situ-associated myoepithelial cells: biologic and diagnostic implications.

Hilson JB, Schnitt SJ, Collins LC.

Am J Surg Pathol. 2009 Feb;33(2):227-32. doi: 10.1097/PAS.0b013e318180431d.

PMID:
18936688
19.

Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile.

Dabbs DJ, Chivukula M, Carter G, Bhargava R.

Mod Pathol. 2006 Nov;19(11):1506-11. Epub 2006 Aug 25.

20.

Distribution of p63, a novel myoepithelial marker, in fine-needle aspiration biopsies of the breast: an analysis of 82 samples.

Reis-Filho JS, Milanezi F, Amendoeira I, Albergaria A, Schmitt FC.

Cancer. 2003 Jun 25;99(3):172-9.

Supplemental Content

Support Center